CDTX - Cidara Therapeutics, Inc.
| Previous Close | 4.00 |
| Open | 4.04 |
| Bid | 4.00 x 1100 |
| Ask | 4.11 x 1300 |
| Day's Range | 3.94 - 4.14 |
| 52 Week Range | 3.65 - 8.80 |
| Volume | 9,081 |
| Avg. Volume | 100,336 |
| Market Cap | 114.034M |
| Beta (3Y Monthly) | 2.43 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.39 |
| Earnings Date | May 12, 2017 - May 15, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 13.19 |
- Business Wire•2 days ago
Cidara Therapeutics to Present New Rezafungin Data at the 2018 Hot Topics in Infectious Diseases Conference
Cidara Therapeutics, Inc. (CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that new data from studies of its lead antifungal rezafungin will be presented at the 2018 Hot Topics in Infectious Diseases (HTIDE) Conference to be held in Mestre, Venice from October 25-26, 2018. Rezafungin is the only once-weekly antifungal product candidate in development for the treatment and prevention of life-threatening invasive fungal infections. Hot Topics in Infectious Diseases (HTIDE) is a bi-annual conference which convenes more than 400 delegates from all over the world to discuss topics on novel approaches to diagnosis and treatment of infectious diseases.
- Business Wire•13 days ago
Cidara Therapeutics Presents Results from Successful Phase 2 STRIVE Trial Evaluating Rezafungin at IDWeek 2018
Cidara Therapeutics, Inc. (CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced the presentation of data from the company’s Phase 2 STRIVE trial of rezafungin at IDWeek 2018, taking place in San Francisco from October 3-7. The STRIVE trial successfully achieved its primary endpoints, demonstrating the efficacy and safety of once-weekly dosing of rezafungin compared to once-daily dosing of caspofungin in patients with candidemia and/or invasive candidiasis.
- Business Wire•20 days ago
Cidara Therapeutics Initiates Phase 3 Trial of Lead Antifungal Rezafungin for Treatment of Invasive Candida Infections
Cidara Therapeutics, Inc. (CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that the first trial site has been activated for ReSTORE, a Phase 3 clinical trial evaluating the efficacy and safety of the company’s lead antifungal, rezafungin, to treat candidemia and invasive candidiasis. Rezafungin is a novel echinocandin antifungal being developed as a once-weekly, high-exposure therapy for the treatment and prevention of serious invasive fungal infections. “Difficult-to-treat, invasive Candida infections are associated with a high mortality and affect the most vulnerable patients.
- Simply Wall St.•22 days ago
Shareholders Should Check If Insiders Own Shares In Cidara Therapeutics Inc (NASDAQ:CDTX)
The big shareholder groups in Cidara Therapeutics Inc (NASDAQ:CDTX) have power over the company. Institutions often own shares in more established companies, while it’s not unusual to see insiders ownRead More...
- Business Wire•22 days ago
FDA Grants QIDP and Fast Track Designations to Cidara Therapeutics’ Rezafungin Prophylaxis Development Program
Cidara Therapeutics, Inc. (CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that the U.S. Food and Drug Administration (FDA) has granted both Qualified Infectious Disease Product (QIDP) and Fast Track designations for the company’s prophylaxis (prevention) development program for lead antifungal product candidate, rezafungin for injection. Specifically, the QIDP designation is for the development of rezafungin for the prevention of invasive fungal infections in adults undergoing allogeneic bone marrow transplantation.
- GlobeNewswire•23 days ago
Cidara Therapeutics to Present at Two Upcoming Investor Conferences
Cidara Therapeutics, Inc. (CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that Jeffrey Stein, Ph.D., president and chief executive officer of Cidara, is scheduled to present at two upcoming investor conferences. Cidara is a clinical-stage biotechnology company focused on developing new anti-infectives that have the potential to transform the standard of care and save or improve patients’ lives. The company is currently advancing its novel echinocandin antifungal, rezafungin acetate, formerly known as CD101 IV, through clinical trials.
- Business Wire•last month
Cidara Therapeutics Appoints David Gollaher, Ph.D., to Board of Directors
Cidara Therapeutics, Inc. (CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced the appointment of industry leader David Gollaher, Ph.D., to the company’s Board of Directors. “With more than 30 years of experience in the biopharma and healthcare industry, Dr. Gollaher is an outstanding addition to our Board,” said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara.
- Business Wire•last month
Cidara Therapeutics to Present Data on Lead Antifungal Rezafungin at IDWeek 2018
Cidara Therapeutics, Inc. (CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that data demonstrating the broad clinical utility and potency of the company’s lead antifungal product candidate, rezafungin, will be presented at IDWeek 2018, being held October 3-7 in San Francisco. Four separate IDWeek presentations will focus on rezafungin, the only once-weekly antifungal product candidate in development for the treatment and prevention of life-threatening invasive fungal infections, and will include the efficacy and safety results from Cidara’s Phase 2 STRIVE trial.
- Business Wire•last month
Cidara Therapeutics to Present New Cloudbreak Data at the ESCMID/ASM Conference and 16th Annual Discovery on Target Meeting
Cidara Therapeutics, Inc. (CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that new data highlighting the company’s innovative Cloudbreak™ immunotherapy discovery platform will be presented at two upcoming conferences. Cloudbreak is a novel platform that pairs potent antimicrobials with agents that redirect the immune system to destroy fungal, bacterial and viral pathogens.
- Associated Press•2 months ago
Cidara Therapeutics: 2Q Earnings Snapshot
The San Diego-based company said it had a loss of $1.13 per share. Losses, adjusted for non-recurring costs, came to 69 cents per share. In the final minutes of trading on Wednesday, the company's shares ...
- GlobeNewswire•2 months ago
Cidara Provides Corporate Update and Reports Second Quarter 2018 Financial Results
SAN DIEGO, Aug. 08, 2018-- Cidara Therapeutics, Inc., a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial results for the three months ended June ...
- Zacks•3 months ago
Cidara Therapeutics Sees Hammer Chart Pattern: Time to Buy?
Cidara Therapeutics has been struggling lately, but the selling pressure may be coming to an end soon.
- Business Wire•4 months ago
Cidara Therapeutics Announces Oral Presentations on Rezafungin at Two Upcoming Global Conferences
Cidara Therapeutics, Inc. (CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that Dr. Taylor Sandison, chief medical officer, will present clinical efficacy and safety data for the company’s lead antifungal rezafungin for the treatment and prevention of invasive fungal infections at two upcoming, global infectious disease conferences. Abstracts highlighting rezafungin data have been accepted at The 20th International Immunocompromised Host Society (ICHS) Symposium in Athens, Greece, taking place June 17-19, 2018, and The International Society for Human and Animal Mycology (ISHAM) Congress in Amsterdam, taking place in The Netherlands, June 30-July 4, 2018.
- PR Newswire•4 months ago
Antimicrobials Working Group Highlights Member Company Participation at ASM Microbe 2018
88 Presentations by Coalition Members During the Annual Meeting WASHINGTON , June 6, 2018 /PRNewswire/ -- The Antimicrobials Working Group (AWG) today announced that 13 of its member companies will present ...
- Business Wire•5 months ago
Data to be Presented at ASM Microbe 2018 Demonstrate the Efficacy and Safety of Cidara’s Rezafungin for the Treatment of Invasive Fungal Infections
Cidara Therapeutics, Inc. (CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that it will present four posters highlighting data from preclinical studies and a clinical trial of rezafungin, its lead antifungal product candidate, at the American Society for Microbiology (ASM) Microbe 2018, being held June 7-11 in Atlanta. Cidara’s presentations will include a late-breaker poster detailing results from the Phase 2 STRIVE clinical trial, which evaluated rezafungin as a once-weekly, high-exposure intravenous therapy for the treatment of serious invasive fungal infections. Preclinical data to be presented include evaluation of the mutant prevention concentration of rezafungin, which may indicate a potential to suppress antifungal resistance.
- Business Wire•5 months ago
Cidara Therapeutics and Rutgers University Awarded $5.5 Million Grant from NIH to Support Development of Novel Immunotherapy Agents Targeting Multi-drug Resistant Gram-negative Bacterial Infections
Cidara Therapeutics, Inc. (CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that it and Rutgers University have been awarded a five-year, $5.5 million partnership grant from the U.S. National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services.
- Associated Press•5 months ago
Cidara Therapeutics: 1Q Earnings Snapshot
The San Diego-based company said it had a loss of 80 cents per share. The results missed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a ...
- PR Newswire•6 months ago
Antimicrobials Working Group Highlights Member Company Participation at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
71 Abstracts to be Presented by Coalition Members During the Annual Meeting WASHINGTON , April 20, 2018 /PRNewswire/ -- The Antimicrobials Working Group (AWG) today announced that thirteen of its member ...
- Business Wire•6 months ago
Cidara Therapeutics to Present Rezafungin Data at the European Congress of Clinical Microbiology and Infectious Diseases 2018 Meeting
Cidara Therapeutics, Inc. , a biotechnology company developing novel anti-infectives including immunotherapies, today announced that data from preclinical studies of its lead antifungal rezafungin will be presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases to be held in Madrid, Spain, April 21-24, 2018.
- ACCESSWIRE•7 months ago
Blog Exposure - Cidara Therapeutics Released Positive Top-line Results from Phase-2 STRIVE Trial Assessing its Lead Antifungal Rezafungin
Stock Monitor: BioTime Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 21, 2018 / Active-Investors.com has just released a free research report on Cidara Therapeutics, Inc. (NASDAQ: CDTX ). If ...
- Zacks•7 months ago
Options Traders Expect Huge Moves in Cidara Therapeutics (CDTX) Stock
Surging implied volatility makes Cidara Therapeutics (CDTX) stock lucrative to the option traders.
